Cancer classification using the Immunoscore: a worldwide task force
Jérôme Galon(Délégation Paris 5), Noriyuki Sato(Sapporo Higashi Tokushukai Hospital), Michele Maio(University of Siena), Réjean Lapointe(Montreal Neurological Institute and Hospital), Gerardo Botti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Samir N. Khleif(Georgetown University), Graham Pawelec(Health Sciences North), Fabio Grizzi(Humanitas University), Bradly G. Wouters(Princess Margaret Cancer Centre), Christoph Huber(University Hospital of Geneva), Cedrik M. Britten(Johannes Gutenberg University Mainz), Jill O’Donnell-Tormey(Cancer Research Institute), Robert D. Hawkins(University of Manchester), Paolo Delrio(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), James P. Allison(The University of Texas MD Anderson Cancer Center), Peter Gibbs(The University of Melbourne), Luigi Laghi(Humanitas University), Ena Wang(Sidra Medical and Research Center), Lotfi Chouchane(Cornell University), Christine Lagorce(Assistance Publique – Hôpitaux de Paris), Giuseppe Masucci(Karolinska University Hospital), Leif Håkansson(Lund University), Francesco M. Marincola(Center for Translational Molecular Medicine), Pamela S. Ohashi(University Health Network), Alessandro Lugli(University of Bern), Carlo Bifulco(Providence Health & Services), Andreas Lundqvist(Karolinska Institutet), Shoichi Hazama(Yamaguchi University), Fernando Vidal‐Vanaclocha(George Washington University), Harpreet Singh‐Jasuja(Immatics Biotechnologies (Germany)), Blaise Clarke(Princess Margaret Cancer Centre), Christian H. Ottensmeier(Clatterbridge Cancer Centre NHS Foundation Trust), Helen K. Angell(Délégation Paris 5), Shuji Ogino(Broad Institute), Sacha Gnjatic(Tisch Hospital), Inti Zlobec(University of Bern), Franck Pagès(Inserm), Michael I. Nishimura(Loyola University Medical Center), Martin Asslaber(Medical University of Graz), Paul Waring(The University of Melbourne), Patricia A. Shaw(Gynecologic Oncology Group), Martin Mihm(Harvard University), H. Zwierzina(Innsbruck Medical University), Yutaka Kawakami(Keio University), Kiyotaka Okuno(Kindai University), Fabiana Tatangelo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Anne Berger(Délégation Paris 5), Sebastian Kreiter(Johannes Gutenberg University Mainz)
Cited by 803
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k